TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS

J. Vojinovic; J. Dehoorne; V. Panaviene; G. Susic; G. Horneff; V. Stanevicha; K. Kobusinska; Z. Żuber; B. Dobrzyniecka; J. Akikusa; T. Avcin; A. Martini; C. Borlenghi; E. Arthur; S. Y. Tatulych; C. Zang; V. Tsekouras; B. Vlahos; N. Ruperto

doi:10.1136/annrheumdis-2022-eular.168

TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS

J. Vojinovic, J. Dehoorne, V. Panaviene, G. Susic, G. Horneff, V. Stanevicha, K. Kobusinska, Z. Żuber, B. Dobrzyniecka, J. Akikusa, T. Avcin, A. Martini, C. Borlenghi, E. Arthur, S. Y. Tatulych, C. Zang, V. Tsekouras, B. Vlahos, N. Ruperto

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in patients (pts) with juvenile idiopathic arthritis (JIA), categorized as extended oligoarticular JIA (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA). Objectives: Evaluation of the efficacy of ETN and its effect on health outcomes over 10 years of follow-up were secondary objectives and are reported here. Methods: Pts (n=127) with eoJIA (n=60; 2-17 years of age), ERA (n=38; 12-17), or PsA (n=29; 12-17) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The study design has been reported previously.1 Efficacy endpoints included proportions of pts achieving JIA American College of Rheumatology (ACR) 30/50/70/90/100 criteria, Juvenile Arthritis Disease Activity Score (JADAS) inactive disease and clinical remission criteria, and sustained clinical remission (ACR criteria) or JADAS ≤1 for 12 continuous months (mths). Exploratory efficacy endpoints included time to fare following ETN withdrawal (based on ≥30% worsening in ≥3/6 ACR Pedi components, with ≥30% improvement in

Original language	English
Article number	POS1293
Pages (from-to)	983-984
Journal	Annals of the Rheumatic Diseases
Volume	81
Issue number	Suppl 1
DOIs	https://doi.org/10.1136/annrheumdis-2022-eular.168
Publication status	Published - 2022
Externally published	Yes
Event	Annual European Congress of Rheumatology (EULAR 2022): EULAR 2022 - virtually, Copenhagen, Denmark Duration: 1 Jun 2022 → 4 Jun 2022 https://congress.eular.org/congress_venue.cfm

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1136/annrheumdis-2022-eular.168

Fingerprint

Dive into the research topics of 'TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS'. Together they form a unique fingerprint.

Cite this

Vojinovic, J., Dehoorne, J., Panaviene, V., Susic, G., Horneff, G., Stanevicha, V., Kobusinska, K., Żuber, Z., Dobrzyniecka, B., Akikusa, J., Avcin, T., Martini, A., Borlenghi, C., Arthur, E., Tatulych, S. Y., Zang, C., Tsekouras, V., Vlahos, B., & Ruperto, N. (2022). TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases, 81(Suppl 1), 983-984. Article POS1293 . https://doi.org/10.1136/annrheumdis-2022-eular.168

@article{498f9cc81c9c4ec7b134bfc74ea11203,

title = "TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS",

abstract = "Background: CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in patients (pts) with juvenile idiopathic arthritis (JIA), categorized as extended oligoarticular JIA (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA). Objectives: Evaluation of the efficacy of ETN and its effect on health outcomes over 10 years of follow-up were secondary objectives and are reported here. Methods: Pts (n=127) with eoJIA (n=60; 2-17 years of age), ERA (n=38; 12-17), or PsA (n=29; 12-17) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The study design has been reported previously.1 Efficacy endpoints included proportions of pts achieving JIA American College of Rheumatology (ACR) 30/50/70/90/100 criteria, Juvenile Arthritis Disease Activity Score (JADAS) inactive disease and clinical remission criteria, and sustained clinical remission (ACR criteria) or JADAS ≤1 for 12 continuous months (mths). Exploratory efficacy endpoints included time to fare following ETN withdrawal (based on ≥30% worsening in ≥3/6 ACR Pedi components, with ≥30% improvement in ",

author = "J. Vojinovic and J. Dehoorne and V. Panaviene and G. Susic and G. Horneff and V. Stanevicha and K. Kobusinska and Z. {\.Z}uber and B. Dobrzyniecka and J. Akikusa and T. Avcin and A. Martini and C. Borlenghi and E. Arthur and Tatulych, {S. Y.} and C. Zang and V. Tsekouras and B. Vlahos and N. Ruperto",

year = "2022",

doi = "10.1136/annrheumdis-2022-eular.168",

language = "English",

volume = "81",

pages = "983--984",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "Suppl 1",

note = "Annual European Congress of Rheumatology (EULAR 2022) : EULAR 2022, EULAR 2022 ; Conference date: 01-06-2022 Through 04-06-2022",

url = "https://congress.eular.org/congress_venue.cfm",

}

Vojinovic, J, Dehoorne, J, Panaviene, V, Susic, G, Horneff, G, Stanevicha, V, Kobusinska, K, Żuber, Z, Dobrzyniecka, B, Akikusa, J, Avcin, T, Martini, A, Borlenghi, C, Arthur, E, Tatulych, SY, Zang, C, Tsekouras, V, Vlahos, B & Ruperto, N 2022, 'TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS', Annals of the Rheumatic Diseases, vol. 81, no. Suppl 1, POS1293 , pp. 983-984. https://doi.org/10.1136/annrheumdis-2022-eular.168

TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS. / Vojinovic, J.; Dehoorne, J.; Panaviene, V. et al.
In: Annals of the Rheumatic Diseases, Vol. 81, No. Suppl 1, POS1293 , 2022, p. 983-984.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS

AU - Vojinovic, J.

AU - Dehoorne, J.

AU - Panaviene, V.

AU - Susic, G.

AU - Horneff, G.

AU - Stanevicha, V.

AU - Kobusinska, K.

AU - Żuber, Z.

AU - Dobrzyniecka, B.

AU - Akikusa, J.

AU - Avcin, T.

AU - Martini, A.

AU - Borlenghi, C.

AU - Arthur, E.

AU - Tatulych, S. Y.

AU - Zang, C.

AU - Tsekouras, V.

AU - Vlahos, B.

AU - Ruperto, N.

PY - 2022

Y1 - 2022

N2 - Background: CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in patients (pts) with juvenile idiopathic arthritis (JIA), categorized as extended oligoarticular JIA (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA). Objectives: Evaluation of the efficacy of ETN and its effect on health outcomes over 10 years of follow-up were secondary objectives and are reported here. Methods: Pts (n=127) with eoJIA (n=60; 2-17 years of age), ERA (n=38; 12-17), or PsA (n=29; 12-17) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The study design has been reported previously.1 Efficacy endpoints included proportions of pts achieving JIA American College of Rheumatology (ACR) 30/50/70/90/100 criteria, Juvenile Arthritis Disease Activity Score (JADAS) inactive disease and clinical remission criteria, and sustained clinical remission (ACR criteria) or JADAS ≤1 for 12 continuous months (mths). Exploratory efficacy endpoints included time to fare following ETN withdrawal (based on ≥30% worsening in ≥3/6 ACR Pedi components, with ≥30% improvement in

AB - Background: CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in patients (pts) with juvenile idiopathic arthritis (JIA), categorized as extended oligoarticular JIA (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA). Objectives: Evaluation of the efficacy of ETN and its effect on health outcomes over 10 years of follow-up were secondary objectives and are reported here. Methods: Pts (n=127) with eoJIA (n=60; 2-17 years of age), ERA (n=38; 12-17), or PsA (n=29; 12-17) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The study design has been reported previously.1 Efficacy endpoints included proportions of pts achieving JIA American College of Rheumatology (ACR) 30/50/70/90/100 criteria, Juvenile Arthritis Disease Activity Score (JADAS) inactive disease and clinical remission criteria, and sustained clinical remission (ACR criteria) or JADAS ≤1 for 12 continuous months (mths). Exploratory efficacy endpoints included time to fare following ETN withdrawal (based on ≥30% worsening in ≥3/6 ACR Pedi components, with ≥30% improvement in

UR - https://www.mendeley.com/catalogue/36c69787-d163-314c-b198-362f28f7c6c5/

U2 - 10.1136/annrheumdis-2022-eular.168

DO - 10.1136/annrheumdis-2022-eular.168

M3 - Meeting Abstract

SN - 0003-4967

VL - 81

SP - 983

EP - 984

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 1

M1 - POS1293

T2 - Annual European Congress of Rheumatology (EULAR 2022)

Y2 - 1 June 2022 through 4 June 2022

ER -

Vojinovic J, Dehoorne J, Panaviene V, Susic G, Horneff G, Stanevicha V et al. TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2022;81(Suppl 1):983-984. POS1293 . doi: 10.1136/annrheumdis-2022-eular.168

TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS

Abstract

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this